




# PHARMACEUTICAL 2018

## KERYX BIOPHARMACEUTICALS INC Rank 288 of 342





# PHARMACEUTICAL 2018

## KERYX BIOPHARMACEUTICALS INC Rank 288 of 342

The relative strengths and weaknesses of KERYX BIOPHARMACEUTICALS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of KERYX BIOPHARMACEUTICALS INC compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 25% points. The greatest weakness of KERYX BIOPHARMACEUTICALS INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 94% points.

The company's Economic Capital Ratio, given in the ranking table, is -113%, being 159% points below the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	141,566
Cost of Goods Sold	0
Intangible Assets	3,208
Liabilities, Current	45,420
Liabilities, Non-Current	894
Other Assets	9,577
Other Compr. Net Income	0
Other Expenses	24,831
Other Liabilities	126,653
Other Net Income	-61,984
Other Revenues	60,641
Property and Equipment	4,521
Research and Development	37,679
Selling, General and Administrative Expense	99,622

Output Variable	Value in 1000 USD
Assets	158,872
Liabilities	172,967
Expenses	162,132
Revenues	60,641
Stockholders Equity	-14,095
Net Income	-163,475
Comprehensive Net Income	-163,475
Economic Capital Ratio	-113%